Dublin, July 01, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy R&D Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.
World revenue for Gene Therapy R&D Market is forecast to surpass US$3.6 billion in 2024, with strong revenue growth through to 2034.
In the past five years, gene therapy has made a remarkable comeback. Advancements in virology, vector and capsid architecture, and manufacturing have led to exciting breakthroughs and regulatory progress, capturing the attention of biotech investors. Biopharma firms are strategizing to gain an edge, expanding facilities, forming partnerships, and collaborating with contract manufacturing organizations (CMOs).
According to a recent report by the Alliance for Regenerative Medicine, over 1,400 global companies are focused on cell and gene therapies (CGTs), with 3,500 therapies in development and over 2,000 active clinical trials. North America leads in clinical trials, followed by the Asia Pacific and Europe, with oncology and rare diseases as the primary therapeutic targets. Venture capital remains the main driver of growth, reflecting enthusiasm for scientific advancements and potential treatment breakthroughs.
The FDA expects to receive over 200 investigational new drug applications for CGTs annually, approving 10 to 20 new therapies per year. In 2024, up to 21 cell therapy and 31 gene therapy launches are anticipated, prompting the FDA to elevate its Office of Tissues and Advanced Therapies (OTAT) within the Center for Biologics Research and Evaluation (CBER). Proposed structural changes aim to enhance review capabilities and expertise to accommodate the growing workload and ensure efficient regulatory processes.
Key Market Dynamics
Market Driving Factors
- Robust Gene Therapy Pipeline to Boost Growth
- Technological Advancements to Fuel Market Growth
- Increasing Financing and Acquisitions by Major Players
- Growing Prevalence of Targeted Diseases Treatment
Market Restraining Factors
- Cell & Gene Therapies Target Specific Diseases
- High Cost to Stifle Gene Therapy R&D Growth
- Regulatory Scenarios to Challenge Industry Growth
Market Opportunities
- Growing Number of Clinical Trials to Offer Lucrative Growth Opportunities
- Facility Expansion Anticipated to Offer Lucrative Growth Prospects
- Artificial Intelligence Can Bring Value to Gene Therapy R&D
Key Questions Answered
- How is the gene therapy R&D market evolving?
- What is driving and restraining the gene therapy R&D market?
- How will each gene therapy R&D submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
- How will the market shares for each gene therapy R&D submarket develop from 2024 to 2034?
- What will be the main driver for the overall market from 2024 to 2034?
- Will leading gene therapy R&D markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
- Who are the leading players and what are their prospects over the forecast period?
- What are the gene therapy R&D projects for these leading companies?
- How will the industry evolve during the period between 2024 and 2034? What are the implications of gene therapy R&D projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the gene therapy R&D market?
- Where is the gene therapy R&D market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
Forecasts to 2034 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2034, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter's Five Forces Analysis, PEST Analysis and recent developments.
Segments Covered in the Report
Disease
- Cancer
- Rare Diseases
- Oncologic
- Non-oncologic
- Cardiovascular Diseases
- Ophthalmic Diseases
- Haematology
- Neurological
- Diabetes Mellitus
- Other Diseases
Vector
- Viral
- Retrovirus
- Adenovirus
- AAV
- Lentivirus
- Others
- Non-viral
- Naked DNA
- Gene Gun
- Electroporation
- Lipofection
Techniques
- Gene Augmentation Therapy
- Gene Replacement Therapy
Participants
- Small/Medium Pharma & Biotech
- Universities & Research Institutes
- Hospitals
- Government & Public Bodies
- Big Pharma
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 22 leading national markets.
The report also includes profiles and for some of the leading companies in the Gene Therapy R&D Market, with a focus on this segment of these companies' operations.
Leading companies profiled in the report
- American Gene Technologies
- Applied Genetic
- Astellas Pharma Inc.
- Bayer
- Benitec BioPharma
- Biogen
- Bluebird Bio
- Bristol Myers Squibb
- Calimmune, Inc. (CSL Behiring)
- Cellectis
- GeneQuine Biotherapeutics
- GenSight Biologics
- Gilead Lifesciences, Inc.
- Novartis AG
- Ocugen, Inc.
- Orchard Therapeutics
- Oxford Biomedica
- Pfizer, Inc.
- REGENXBIO Inc.
- Sangamo Therapeutics, Inc.
- Sanofi
- Sarepta Therapeutics, Inc.
- Spark Therapeutics (Subsidiary of Roche)
- Takeda Pharmaceuticals
- Taysha GTx
- Transgene
- UniQure N. V.
- ViGeneron
- Voyager Therapeutics
For more information about this report visit https://www.researchandmarkets.com/r/gzytst
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
